Company profile
APREA THERAPEUTICS, INC.
NASDAQ:APREBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EPRENETAPOPT | phase3 | — | 9 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03391050 | phase1_2 | terminated | 2018-01-18 | 2018-08-08 | Aprea Therapeutics | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma |
| NCT03745716 | phase3 | completed | 2019-01-11 | 2020-11-27 | Aprea Therapeutics | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) |
| NCT04419389 | phase1_2 | terminated | 2021-03-02 | 2021-08-23 | Aprea Therapeutics | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) |
| NCT03931291 | phase2 | completed | 2019-09-16 | 2021-08-27 | Aprea Therapeutics | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant |
| NCT04214860 | phase1 | completed | 2019-12-13 | 2022-01-14 | Aprea Therapeutics | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies |
FDA applications (0)
No records yet.